Significance of the YOSEMITE and RHINE 2-year DMO clinical trial results
June 28, 2022
In the study, the faricimab molecule, which is a combined anti-Ang2 and anti-VEGF, performed better than the aflibercept drug in many different ways. Rishi P. Singh, MD, FASRS, summarizes some of these key findings.